Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID-CKD: Rapid Therapy Initiation in CKD and T2D
NCT07547878Phase 4Enrolling by invitation
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of finerenone, semaglutide, benazepril, captopril, enalapril in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), sponsored by Baylor Scott & White Research Institute. Started Apr 2026; status: enrolling by invitation.
02
Drugs
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07547878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547878.